Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Skye Bioscience Inc (OP: SKYE ) N/A UNCHANGED Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Skye Bioscience Inc < Previous 1 2 3 Next > Skye Bioscience Announces $40 Million Private Placement Equity Financing March 11, 2024 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology... Via Newsfile Skye Bioscience to Present at Oppenheimer Investor Conference February 07, 2024 San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused... Via Newsfile Skye Bioscience And 2 Other Penny Stocks Insiders Are Buying February 05, 2024 The Dow Jones index closed higher by more than 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... Via Benzinga Topics Stocks Exposures US Equities Skye Bioscience Announces $50.25 Million Private Placement Equity Financing January 29, 2024 San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("the Company"), a clinical stage biotechnology... Via Newsfile Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease January 09, 2024 San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa December 05, 2023 San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a... Via Newsfile Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit November 21, 2023 San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs... Via Newsfile Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma October 25, 2023 • SBI-100 OE is well tolerated, with low rate of hyperaemia... Via Newsfile CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System" October 20, 2023 This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego, California--(Newsfile Corp.... Via Newsfile Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary... Via Newsfile Marijuana Stock Movers For August 23, 2023 August 23, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Cannabis Stock Gainers And Losers From August 25, 2023 August 25, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor August 21, 2023 Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid... Via Benzinga Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody August 21, 2023 New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of... Via Newsfile Cannabis Stock Gainers And Losers From August 24, 2023 August 24, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Cannabis Stock Movers For August 18, 2023 August 18, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Marijuana Stock Movers For August 22, 2023 August 22, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference August 14, 2023 San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a... Via Newsfile Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers August 07, 2023 Via Benzinga Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023 August 21, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers August 17, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Cannabis Stock Gainers And Losers From August 16, 2023 August 16, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Cannabis Stock Gainers And Losers From August 14, 2023 August 14, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Cannabis Stock Gainers And Losers From August 11, 2023 August 11, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Marijuana Stock Movers For August 8, 2023 August 08, 2023 Via Benzinga Marijuana Stock Movers For August 2, 2023 August 02, 2023 Via Benzinga Marijuana Stock Movers For August 1, 2023 August 01, 2023 Via Benzinga Marijuana Stock Movers For July 31, 2023 July 31, 2023 Via Benzinga Cannabis Stock Gainers And Losers From July 28, 2023 July 28, 2023 Via Benzinga Cannabis Stock Gainers And Losers From July 26, 2023 July 26, 2023 Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
